Literature DB >> 14709797

Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure.

Luis Girotti1, Manuel Lago, Oscar Ianovsky, Marcelo V Elizari, Andrés Dini, Santiago Pérez Lloret, Liliana E Albornoz, Daniel P Cardinali.   

Abstract

OBJECTIVE: To assess urinary 6-sulfatoxymelatonin excretion in patients admitted to the hospital because of congestive heart failure (CHF).
METHODS: Urinary 6-sulfatoxymelatonin was measured by a specific radioimmunoassay in 33 hospitalized patients with CHF and in 146 healthy ambulatory volunteers. Individuals with hepatic or renal failure were excluded from the sample. Data were analyzed by the Mann-Whitney test and regression analysis.
RESULTS: 6-Sulfatoxymelatonin levels were significantly lower in CHF patients than controls (median 2.6 vs 6.02 microg, p < 0.0001). This decrease was observed regardless of beta-adrenergic blocker or benzodiazepine medication. A significant decrease in 6-sulfatoxymelatonin excretion occurred with age. There were no significant differences in urinary 6-sulfatoxymelatonin levels between chronic and acute CHF patients.
CONCLUSIONS: The results suggest that circulating melatonin levels are low in patients with CHF. Such a decrease may precede aggravation of heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14709797     DOI: 10.1385/ENDO:22:3:245

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure.

Authors:  R Ferrari; A F Panzali; P A Poole-Wilson; I S Anand
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

3.  Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function.

Authors:  J J Baskett; J F Cockrem; T A Antunovich
Journal:  J Pineal Res       Date:  1998-01       Impact factor: 13.007

4.  Melatonin-induced relaxation of rat aorta: interaction with adrenergic agonists.

Authors:  L B Weekley
Journal:  J Pineal Res       Date:  1991-08       Impact factor: 13.007

5.  Neuropeptide Y increases intracellular calcium in rat pinealocytes.

Authors:  V Simonneaux; J L Rodeau; C Calgari; P Pévet
Journal:  Eur J Neurosci       Date:  1999-02       Impact factor: 3.386

6.  Role of prostaglandins in rat pineal neuroeffector junction. Changes in melatonin and norepinephrine release in vitro.

Authors:  D P Cardinali; M N Rita; E Pereyra; C G Solveyra
Journal:  Endocrinology       Date:  1982-08       Impact factor: 4.736

7.  Basic aspects of melatonin action.

Authors:  D P Cardinali; P Pévet
Journal:  Sleep Med Rev       Date:  1998-08       Impact factor: 11.609

8.  In vitro effect of neuropeptide Y on melatonin and norepinephrine release in rat pineal gland.

Authors:  M I Vacas; M I Sarmiento; E N Pereyra; G S Etchegoyen; D P Cardinali
Journal:  Cell Mol Neurobiol       Date:  1987-09       Impact factor: 5.046

9.  Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol.

Authors:  J Arendt; C Bojkowski; C Franey; J Wright; V Marks
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

10.  Increase in bicycloprostaglandin E2 metabolite in congestive heart failure in response to captopril.

Authors:  B Stanek; C Punzengruber; K Silberbauer
Journal:  Clin Cardiol       Date:  1989-02       Impact factor: 2.882

View more
  15 in total

1.  MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.

Authors:  Radhika R Tunstall; Praveen Shukla; Anna Grazul-Bilska; Chengwen Sun; Stephen T O'Rourke
Journal:  J Pharmacol Exp Ther       Date:  2010-10-19       Impact factor: 4.030

2.  Aerobic exercise enhanced endothelium-dependent vasorelaxation in mesenteric arteries in spontaneously hypertensive rats: the role of melatonin.

Authors:  Fang Qiu; Xiaodong Liu; Yanyan Zhang; Ying Wu; Daliao Xiao; Lijun Shi
Journal:  Hypertens Res       Date:  2018-07-02       Impact factor: 3.872

3.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

4.  Measurement of melatonin in body fluids: standards, protocols and procedures.

Authors:  Eduardo Alves de Almeida; Paolo Di Mascio; Tatsuo Harumi; D Warren Spence; Adam Moscovitch; Rüdiger Hardeland; Daniel P Cardinali; Gregory M Brown; S R Pandi-Perumal
Journal:  Childs Nerv Syst       Date:  2010-11-21       Impact factor: 1.475

5.  Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial.

Authors:  Shervin G Hoseini; Kiyan Heshmat-Ghahdarijani; Saeid Khosrawi; Mohammad Garakyaraghi; Davood Shafie; Marjan Mansourian; Hamidreza Roohafza; Elham Azizi; Masoumeh Sadeghi
Journal:  Clin Cardiol       Date:  2022-02-16       Impact factor: 3.287

6.  Melatonin suppresses hypoxia-induced migration of HUVECs via inhibition of ERK/Rac1 activation.

Authors:  Ling Yang; Jianchao Zheng; Rui Xu; Yujie Zhang; Luo Gu; Jing Dong; Yichao Zhu; Ruijue Zhou; Lu Zheng; Xiaoying Zhang; Jun Du
Journal:  Int J Mol Sci       Date:  2014-08-13       Impact factor: 5.923

Review 7.  Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.

Authors:  Anastasia Otamas; Peter J Grant; Ramzi A Ajjan
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

8.  Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds.

Authors:  Ana B Cerezo; Ruth Hornedo-Ortega; M Antonia Álvarez-Fernández; Ana M Troncoso; M Carmen García-Parrilla
Journal:  Nutrients       Date:  2017-03-08       Impact factor: 5.717

Review 9.  Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?

Authors:  Zukiswa Jiki; Sandrine Lecour; Frederic Nduhirabandi
Journal:  Front Physiol       Date:  2018-05-17       Impact factor: 4.566

Review 10.  Melatonin in Heart Failure: A Promising Therapeutic Strategy?

Authors:  Frederic Nduhirabandi; Gerald J Maarman
Journal:  Molecules       Date:  2018-07-22       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.